Recombinant VEGFR2 (Ramucirumab Biosimilar) antibody

Catalog No. ABIN7795122

The Mouse Monoclonal anti-VEGFR2 (Ramucirumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect VEGFR2 (Ramucirumab Biosimilar) in samples from Human.

Quick Overview for Recombinant VEGFR2 (Ramucirumab Biosimilar) antibody (ABIN7795122)

Target: VEGFR2 (Ramucirumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This VEGFR2 (Ramucirumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-VEGFR2 (Ramucirumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody

Characteristics: What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human VEGFR2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for VEGFR2 (Ramucirumab Biosimilar)

Target: VEGFR2 (Ramucirumab Biosimilar)

Alternative Name: Ramucirumab Biosimilar

Target Type: Biosimilar